CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
ranibizumabdrug
Likely dose
ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01810042
NCT01810042Phase 4Completed
CompareCT.gov

A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration

Pusan National University Hospital·interventional·Posted Mar 13, 2013·Updated May 4, 2016

In Brief

A Phase 4 clinical trial evaluating ranibizumab for Exudative Age-related Macular Degeneration. Completed, enrolled 49 participants across 2 sites.

Detailed Summary

Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation of the treatment. The changes of the CNV vascular structure is expected to provide information regarding recurrence. In the eyes that the vascular structure is clearly seen in indocyanine green angiography (ICGA), the vascular changes after ranibizumab injections will be investigated prospectively.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExudative Age-related Macular Degeneration
CountriesSouth Korea
CollaboratorsNovartis

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 13, 2013
Enrollment StartOct 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.3 years ago

Interventions

ranibizumabdrug

0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.